News Summary

Miist Therapeutics, founded by Dalton Signor, a former university student, has developed an innovative inhaler aimed at helping individuals quit smoking and manage migraines. The startup, co-founded with physicist Jeff Schuster and biomedical engineer Eric Ezerins, secured $7 million in seed funding from investors including Refactor Capital, 1517 Fund, and Freeflow Ventures. The inhaler, which functions similarly to a vaping device, offers rapid relief by delivering medication directly to the lungs for fast absorption. Phase I trials showed a significant reduction in cravings for smokers, with a 92% elimination in just two minutes. Miist is also exploring the use of its technology for administering migraine medication and other potential treatments. The company is preparing for a Phase II trial for its smoking cessation technology and continues to test migraine drugs in the lab. This innovation positions Miist as a potential leader in the field, alongside competitors like Qnovia, which has also developed a vape-like device for similar uses.